Oncology Medical News about pediatric differentiated thyroid carcinoma;disease free survival;risk factor analysis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pediatric differentiated thyroid carcinoma in stage I: risk factor analysis for disease free survival
BMC Cancer, 09/04/09

Wada N et al. – Male gender, tumor stage, and lymphadenopathy are risk factors for DFS in stage I pediatric DTC patients. Aggressive treatment (total thyroidectomy, node dissection, and RI therapy) is considered appropriate for patients with risk factors, whereas conservative or stepwise approach may be acceptable for other patients.

Methods

57 TNM stage I patients (≤ 15 years ) with DTC (46 papillary and 11 follicular) who underwent initial treatment (7 males and 50 females; mean age, 13.1 years; mean follow-up, 17.4 years) were studied

Results

Extrathyroid extension and clinical lymphadenopathy at diagnosis were found in 7 and 12 patients, respectively
Subtotal/total thyroidectomy was performed in 23 patients, modified neck dissection in 38, and radioactive iodine therapy in 10
Pathologic node metastasis was confirmed in 37 patients (64.9%)
Fifteen patients (26.3%) exhibited local recurrence and 3 of them also developed metachronous lung metastasis
10 of15 achieved disease-free after further treatments and no patients died of disease
Male gender, advanced tumor (T3, 4a) stage, and clinical lymphadenopathy were risk factors for DFS in stage I pediatric patients

<< Previous
Phase III study of pemetrexed plus carboplatin compared with...

Next >>
Bevacizumab alone and in combination with irinotecan in recurrent...

Diffuse Sclerosing Variant Is a Major Subtype of Papillary Thyroid Carcinoma in the Young
Thyroid, 11/06/09 Relevance Score: 82%

RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact
Journal of Clinical Endocrinology and Metabolism, 10/21/09 Relevance Score: 81%

Thyroid Ultrasonography
World Journal of Surgery, 10/20/09 Relevance Score: 80%

Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas
British Journal of Cancer, 10/08/09 Relevance Score: 80%

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
European Journal of Endocrinology, 10/06/09 Relevance Score: 79%